Literature DB >> 6352194

Home positive-pressure ventilation. Twenty years' experience.

M L Splaingard, R C Frates, G M Harrison, R E Carter, L S Jefferson.   

Abstract

We studied retrospectively 26 adults and 21 children with chronic respiratory failure whose condition was managed at home using positive-pressure ventilators in order to ascertain the outcome, benefits, and complications of this form of management. Twenty-six (55 percent) of the patients had injuries to the spinal cord. Among the 47 patients, nine were eventually weaned from the ventilator, and two died at home because of disconnection from their ventilators. Using life-table analysis, projected three-year survival was 74 percent for patients without spinal injury and 63 percent for patients with spinal injury. Mortality was greater for children than for adults. For a majority of patients, the cost of management at home was significantly less than management in the hospital, depending largely on the level of nursing care required. We suggest that mechanical ventilation at home may be a reasonable alternative to prolonged hospitalization for medically stable ventilator-dependent adults and children.

Entities:  

Mesh:

Year:  1983        PMID: 6352194     DOI: 10.1378/chest.84.4.376

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Respiratory failure and mechanical ventilation: pathophysiology and methods of promoting weaning.

Authors:  J P Karpel; T K Aldrich
Journal:  Lung       Date:  1986       Impact factor: 2.584

2.  Technology-dependent children in New York State.

Authors:  B N Millner
Journal:  Bull N Y Acad Med       Date:  1991 Mar-Apr

3.  Ventilation or dignified death for patients with high tetraplegia.

Authors:  B P Gardner; F Theocleous; J W Watt; K R Krishnan
Journal:  Br Med J (Clin Res Ed)       Date:  1985-12-07

4.  Assisted Breathing with a Diaphragm Pacing System: A Systematic Review.

Authors:  A La Woo; Ha Jin Tchoe; Hae Won Shin; Chae Min Shin; Chae Man Lim
Journal:  Yonsei Med J       Date:  2020-12       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.